WomEC Reshaping women's health through the understanding of gynecological fluids. WomEC: Antibody-based IVD test based on 5 novel protein biomarkers quantified in liquid biopsy
- Coordinator
- Mimark Diagnostics SL, Spain
- Runs
- 1 October 2023 to 30 June 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.9m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190153073
What the project is doing
In the project's own words, from its summary on CORDIS.
WomEC is the future of endometrial cancer (EC) diagnosis. It is an in vitro diagnostic test for EC based on 5 novel protein biomarkers that are analyzed in the fluid of a pipelle biopsy, providing a 97% Negative Predictive Value. WomEC has been verified in 4 clinical retrospective studies in 530 patients that resulted in two patents. A verified immunoassay prototype incorporating a proprietary algorithm and antibodies will be completed by January 2023 with clinical validation and commercialization expected for 2024.
WomEC is targeted at public and private hospital systems (clinical laboratories) and will benefits woman undergoing the diagnostic process by providing: a faster, more accurate diagnosis, with fewer complications by eliminating the need for invasive tests; and by providing tumor histologic information to improve clinical decision making and optimize surgical treatment leading to a better quality of life, increased life expectancy and reduced cost of care.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Mimark Diagnostics SL | Barcelona | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI